Author

Franck Gueneau

Observed name: F. Gueneau

Institution: Light Chain Bioscience (Switzerland)

Observed institutions: Center of Immunology Pierre Fabre, Centre for Genomic Regulation, Light Chain Bioscience (Switzerland)

ORCID: 0000-0003-0054-6575

Observed ORCID: 0000-0003-0054-6575

OpenAlex ID: A5053181303

By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection

2010 · U. Ravn, F. Gueneau, et al. · Nucleic Acids Research · 181

PDF

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG

2015 · Nicolas Fischer, Greg Elson, et al. · Nature Communications · 117

PDF

Deep sequencing of phage display libraries to support antibody discovery

2013 · Ulla Ravn, Gérard Didelot, et al. · Methods · 117

De novoisolation of antibodies with pH-dependent binding properties

2015 · Pauline Bonvin, Sophie Venet, et al. · mAbs · 54

PDF

Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent

2009 · Séverine Fagète, Ulla Ravn, et al. · mAbs · 29

PDF

Transferring the Characteristics of Naturally Occurring and Biased Antibody Repertoires to Human Antibody Libraries by Trapping CDRH3 Sequences

2012 · Sophie Venet, Ulla Ravn, et al. · PLoS ONE · 24

PDF

Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine

2017 · Pauline Bonvin, Franck Gueneau, et al. · Journal of Biological Chemistry · 20

PDF

Recombinant protein production driven by the tryptophan promoter is tightly controlled in ICONE 200, a new genetically engineeredE. coli mutant

2000 · L. Chevalet, A. Robert, et al. · Biotechnology and Bioengineering · 19

Rapid, simple and high yield production of recombinant proteins in mammalian cells using a versatile episomal system

2010 · Giovanni Magistrelli, Pauline Malinge, et al. · Protein Expression and Purification · 18

Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active

2005 · Giovanni Magistrelli, Franck Gueneau, et al. · Biochemical and Biophysical Research Communications · 18

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12

PDF

Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments

2017 · Séverine Fagète, Ledicia Botas-Perez, et al. · Protein Engineering Design and Selection · 6

PDF

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1

2024 · Pauline Malinge, Xavier Chauchet, et al. · mAbs · 3

Dual Specificity of Anti-CXCL10-CXCL9 Antibodies Is Governed by Structural Mimicry

2011 · Séverine Fagète, François Rousseau, et al. · Journal of Biological Chemistry · 3

752P Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer

2022 · A. Seckinger, S. Majocchi, et al. · Annals of Oncology · 2

PDF

Round optimization for improved discovery of native bispecific antibodies

2018 · F. Gueneau, U. Ravn, et al. · Methods · 2

Generation of FcRH5xCD28 Bispecific Antibodies Synergizing with T-Cell Engagers for Enhanced Multiple Myeloma Treatment

2024 · Sara Majocchi, Valéry Moine, et al. · Blood · 1

PDF

Abstract B54: Antagonizing CD47-SIRP alpha interaction with a bispecific antibody: A novel cancer immunotherapy approach

2015 · Krzysztof Masternak, Zoe Johnson, et al. · Cancer Immunology Research · 1

A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer’s brain extracts

2026 · Eric Hatterer, Lucile Broyer, et al. · Alzheimer s Research & Therapy

Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control